Osteoporosis Drugs Market Size by Application, Type, Regional, Industry
Statistics & Forecast 2021 - 2025
Global Osteoporosis Drugs market Size by Type, End User and Application: Global Opportunity
Analysis and Industry Forecast, 2020-2025. The base year considered for the study is 2020, and the
forecast has been provided for the period from 2020 to 2025.
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is
the most common reason for a broken bone among the elderly. Bones that commonly break include
the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically
no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or
spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur
following a broken bone.
Osteoporosis Drugs is a kind of medicine for Osteoporosis, such as Fosamax, Actonel, Boniva,
Zoledronic Acid (Reclast or Zometa) and others.
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of
bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly
increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the
first fracture occurs. Osteoporosis drugs are a kind of medicine for Osteoporosis. The types of
osteoporosis drugs mainly include antiresorptive drugs and anabolic drugs.
The Brazil osteoporosis drugs is Very concentrated, the sales of top eight manufacturers account
exceeds 70% of Brazil sales.
The antiresorptive drugs is the main types of osteoporosis drugs. In 2015, the sales revenue of
antiresorptive drugs is about 109 M USD; its proportion of total osteoporosis drugs exceeds 73%.
According to this study Osteoporosis Drugs market will register a xx% CAGR in terms of revenue,
the global market size will reach US$ xx million by 2025, from US$ xx million in 2020.
The research report offers